Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15883864 | 1.00 | APLNR (0.41) | APLNREPHX1HIF1AKEAP1NFE2L2 | |
| SCHEMBL19040708 | 1.00 | APLNR (0.41) | APLNREPHX1HIF1AKEAP1NFE2L2 | |
| SCHEMBL19040755 | 0.85 | APLNR (0.52) | APLNREPHX1HIF1AKEAP1NFE2L2 | |
| (Isothiocyanatomethyl)Cyclohexane SCHEMBL1448756 | 0.80 | KEAP1 (0.42) | APLNREPHX1HIF1AKEAP1NFE2L2 | |
| SCHEMBL941091 | 0.78 | KEAP1 (0.34) | APLNRKEAP1NFE2L2 | |
| SCHEMBL6538414 | 0.77 | — | — | |
| SCHEMBL822852 | 0.76 | EPHX1 (0.54) | EPHX1HIF1AALDH1A1 | |
| SCHEMBL8156464 | 0.76 | ALDH1A1 (0.55) | EPHX1HIF1AALDH1A1 | |
| SCHEMBL13459214 | 0.75 | APLNR (0.72) | APLNREPHX1HIF1AALDH1A1 | |
| SCHEMBL16307180 | 0.75 | APLNR (0.72) | APLNREPHX1HIF1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160022624-A1 | Method for Treating Eczema | THE WILLIAM M YARBROUGH FOUNDATION | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022624-A1 | Method for Treating Eczema | CCL11, TYR, ITCH | APLNR 1930/4885EPHX1 356/4885HIF1A 2576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.